212 related articles for article (PubMed ID: 38715072)
1. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.
Kundu M; Butti R; Panda VK; Malhotra D; Das S; Mitra T; Kapse P; Gosavi SW; Kundu GC
Mol Cancer; 2024 May; 23(1):92. PubMed ID: 38715072
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance.
Erin N; Grahovac J; Brozovic A; Efferth T
Drug Resist Updat; 2020 Dec; 53():100715. PubMed ID: 32679188
[TBL] [Abstract][Full Text] [Related]
3. Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model.
Nascimento C; Ferreira F
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188587. PubMed ID: 34237352
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Associated Macrophages: Critical Players in Drug Resistance of Breast Cancer.
Xiao M; He J; Yin L; Chen X; Zu X; Shen Y
Front Immunol; 2021; 12():799428. PubMed ID: 34992609
[TBL] [Abstract][Full Text] [Related]
5. Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance.
Khalaf K; Hana D; Chou JT; Singh C; Mackiewicz A; Kaczmarek M
Front Immunol; 2021; 12():656364. PubMed ID: 34122412
[TBL] [Abstract][Full Text] [Related]
6. Monocytes educated by cancer-associated fibroblasts secrete exosomal miR-181a to activate AKT signaling in breast cancer cells.
Pakravan K; Mossahebi-Mohammadi M; Ghazimoradi MH; Cho WC; Sadeghizadeh M; Babashah S
J Transl Med; 2022 Dec; 20(1):559. PubMed ID: 36463188
[TBL] [Abstract][Full Text] [Related]
7. Potential therapeutic targets in myeloid cell therapy for overcoming chemoresistance and immune suppression in gastrointestinal tumors.
Fan J; Zhu J; Zhu H; Xu H
Crit Rev Oncol Hematol; 2024 Jun; 198():104362. PubMed ID: 38614267
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblasts promote an immunosuppressive microenvironment through the induction and accumulation of protumoral macrophages.
Takahashi H; Sakakura K; Kudo T; Toyoda M; Kaira K; Oyama T; Chikamatsu K
Oncotarget; 2017 Jan; 8(5):8633-8647. PubMed ID: 28052009
[TBL] [Abstract][Full Text] [Related]
9. Supramolecular Peptide Amphiphile Nanospheres Reprogram Tumor-associated Macrophage to Reshape the Immune Microenvironment for Enhanced Breast Cancer Immunotherapy.
Xiao Q; Huang J; Wang X; Chen Z; Zhang W; Liu F; Li J; Yang Z; Zhan J; Cai Y
Small; 2024 May; 20(21):e2307390. PubMed ID: 38100300
[TBL] [Abstract][Full Text] [Related]
10. Cancer associated fibroblasts sculpt tumour microenvironment by recruiting monocytes and inducing immunosuppressive PD-1
Gok Yavuz B; Gunaydin G; Gedik ME; Kosemehmetoglu K; Karakoc D; Ozgur F; Guc D
Sci Rep; 2019 Feb; 9(1):3172. PubMed ID: 30816272
[TBL] [Abstract][Full Text] [Related]
11. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
[TBL] [Abstract][Full Text] [Related]
12. TFEB is a master regulator of tumor-associated macrophages in breast cancer.
Li Y; Hodge J; Liu Q; Wang J; Wang Y; Evans TD; Altomare D; Yao Y; Murphy EA; Razani B; Fan D
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487570
[TBL] [Abstract][Full Text] [Related]
13. The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.
Mehraj U; Ganai RA; Macha MA; Hamid A; Zargar MA; Bhat AA; Nasser MW; Haris M; Batra SK; Alshehri B; Al-Baradie RS; Mir MA; Wani NA
Cell Oncol (Dordr); 2021 Dec; 44(6):1209-1229. PubMed ID: 34528143
[TBL] [Abstract][Full Text] [Related]
14. Nanomaterials in modulating tumor-associated macrophages and enhancing immunotherapy.
Liang C; Zhang Y; Wang S; Jiao W; Guo J; Zhang N; Liu X
J Mater Chem B; 2024 May; 12(20):4809-4823. PubMed ID: 38695349
[TBL] [Abstract][Full Text] [Related]
15. Targeting tumor-associated macrophages as an antitumor strategy.
Cheng N; Bai X; Shu Y; Ahmad O; Shen P
Biochem Pharmacol; 2021 Jan; 183():114354. PubMed ID: 33279498
[TBL] [Abstract][Full Text] [Related]
16. Tumor-associated macrophages in immunotherapy.
Yan S; Wan G
FEBS J; 2021 Nov; 288(21):6174-6186. PubMed ID: 33492779
[TBL] [Abstract][Full Text] [Related]
17. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
[TBL] [Abstract][Full Text] [Related]
18. Emerging Role of Cancer-Associated Fibroblasts in Progression and Treatment of Hepatocellular Carcinoma.
Akkız H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835352
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Associated Macrophages as Multifaceted Regulators of Breast Tumor Growth.
Munir MT; Kay MK; Kang MH; Rahman MM; Al-Harrasi A; Choudhury M; Moustaid-Moussa N; Hussain F; Rahman SM
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207035
[TBL] [Abstract][Full Text] [Related]
20. Progress in the Understanding of the Immune Microenvironment and Immunotherapy in Malignant Pleural Mesothelioma.
Cheng L; Li N; Xu XL; Mao WM
Curr Drug Targets; 2020; 21(15):1606-1612. PubMed ID: 32682370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
